Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
MALE
NCT05530655

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Led by University of Rochester · Updated on 2026-01-13

30

Participants Needed

1

Research Sites

201 weeks

Total Duration

On this page

Sponsors

U

University of Rochester

Lead Sponsor

M

Medical College of Wisconsin

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

CONDITIONS

Official Title

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Who Can Participate

Age: 18Years - 70Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed diagnosis of prostate adenocarcinoma and candidate for curative-intent external beam radiation therapy (primary, adjuvant, or salvage) with or without androgen deprivation therapy
  • Stage M0 based on standard imaging
  • Able to read English
  • Psychological and general health suitable for study completion and follow-up
  • Age 18 to under 70 years
  • ECOG performance status 0 to 2 within 180 days before enrollment
  • Adequate renal function with creatinine clearance over 30 mL/min within 30 days before registration
  • Adequate hematologic and hepatic function within 90 days before registration, including hemoglobin 9.0 g/dL or higher and platelet count 100,000/µL or higher
  • Baseline systolic blood pressure over 130
Not Eligible

You will not qualify if you...

  • Prior pelvic radiotherapy
  • Use of lisinopril or other renin-angiotensin system modifying drugs within two months before registration
  • Prior allergic reaction to lisinopril

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Wilmot Cancer Institute

Rochester, New York, United States, 14642

Actively Recruiting

Loading map...

Research Team

T

Therese Smudzin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here